Mosaic Clinical Technologies, a wholly-owned subsidiary of Radiology Partners, has announced that its AI unit, Cognita, has earned US FDA Breakthrough Device designation for Cognita Chest X-Ray (CXR) across multiple critical indications. 

 

This marks a first in the industry: Cognita CXR is the first generative AI model in radiology—and among the very few AI solutions in the field—to receive this prestigious designation.

 

Unlike traditional imaging AI systems that flag individual findings, Cognita CXR leverages a proprietary vision-language model to analyze full chest X-ray studies and generate comprehensive preliminary findings. These AI-generated results are then reviewed and finalized by licensed radiologists, fully integrating into existing radiology workflows.

 

Preliminary internal validation shows promising results: radiologists using Cognita CXR achieved enhanced detection of up to 16%–65% for certain significant findings, and interpretation efficiency improved by 18% on average.

 

The FDA’s Breakthrough Device Program accelerates the development and review of technologies that could significantly improve patient care for life-threatening or irreversibly debilitating conditions. The designation allows Cognita closer collaboration with the FDA, helping bring this innovation into a U.S. healthcare system under strain from acute diagnostic capacity shortages.

 

“Breakthrough Device Designation marks a significant milestone for Cognita CXR,” said Dr. Nina Kottler, Chief Medical AI Officer at Mosaic Clinical Technologies. 

 

“It reflects the urgency of the capacity crisis in radiology and provides the opportunity to work closely with the FDA as we advance through the regulatory process. We believe this is an important step toward bringing AI into everyday radiology practice in a way that enables physicians to practice at the top of their license and expands access to high-quality imaging care worldwide.”

 

Global demand for diagnostic imaging is rising, while the supply of radiologists remains constrained. This imbalance drives longer patient wait times, operational challenges, diagnostic errors, and burnout. Cognita is actively expanding its AI solutions to interpret all X-ray types and 3D CT imaging across anatomies, fully integrating into the Mosaic OS platform.

 

“Building generative AI that can interpret medical images is one of the most complex challenges in applied AI. Inputs can contain up to 1 billion pixels, encoding entire medical textbooks' worth of information. On top of this, real-world radiology is defined by corner cases,” said Louis Blankemeier, co-founder and CEO of Cognita. 

 

“It requires advanced model architectures, methods breakthroughs, large-scale, real-world clinical data, and reinforcement learning through continuous radiologist feedback. The FDA’s Breakthrough Device Designation enables closer collaboration as we continue evaluating this approach in clinical settings through Radiology Partners’ network.”

 

“Radiology Partners was founded to transform how radiology is practiced and delivered,” said Rich Whitney, Chairman and CEO of Radiology Partners. “The Breakthrough Device Designation for Cognita reflects our commitment to pairing great physicians with advanced technology to address the growing demand for diagnostic imaging while meaningfully improving the diagnostic value we offer to clients and patients.”